234 related articles for article (PubMed ID: 20586517)
1. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model.
Nuijten M; Andress DL; Marx SE; Curry AS; Sterz R
Clin Drug Investig; 2010; 30(8):545-57. PubMed ID: 20586517
[TBL] [Abstract][Full Text] [Related]
2. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.
Nuijten M; Andress DL; Marx SE; Sterz R
Curr Med Res Opin; 2009 May; 25(5):1221-34. PubMed ID: 19335321
[TBL] [Abstract][Full Text] [Related]
3. Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected].
Nuijten M; Roggeri DP; Roggeri A; Novelli P; Marshall TS
Clin Drug Investig; 2015 Apr; 35(4):229-38. PubMed ID: 25724153
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD.
Kalantar-Zadeh K; Hollenbeak CS; Arguello R; Snyder S; Ashfaq A
J Med Econ; 2020 Mar; 23(3):308-315. PubMed ID: 31726882
[No Abstract] [Full Text] [Related]
5. Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis.
Zhang Z; Cai L; Wu H; Xu X; Fang W; He X; Wang X; Li X
Front Public Health; 2021; 9():712027. PubMed ID: 34368073
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective.
Menezes FG; Abreu RM; Itria A
J Bras Nefrol; 2016; 38(3):313-319. PubMed ID: 27737389
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Sharma A; Marshall TS; Khan SS; Johns B
Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
9. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.
Rosery H; Bergemann R; Marx SE; Boehnke A; Melnick J; Sterz R; Williams L
Clin Drug Investig; 2006; 26(11):629-38. PubMed ID: 17163297
[TBL] [Abstract][Full Text] [Related]
10. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Cai P; Tang X; Qin W; Ji L; Li Z
Int Urol Nephrol; 2016 Apr; 48(4):571-84. PubMed ID: 26748501
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.
Hervás Sánchez JG; Prados Garrido MD; Polo Moyano A; Cerezo Morales S
Nefrologia; 2011; 31(6):697-706. PubMed ID: 22130286
[TBL] [Abstract][Full Text] [Related]
13. Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital.
Manjarres L; Sanchez P; Cabezas MC; Fornasini M; Freire V; Albert A
BMC Health Serv Res; 2016 Aug; 16(1):443. PubMed ID: 27566059
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of paricalcitol in patients with chronic kidney disease.
Dyer CA
Expert Opin Drug Saf; 2013 Sep; 12(5):717-28. PubMed ID: 23621417
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
Xie Y; Su P; Sun Y; Zhang H; Zhao R; Li L; Meng L
BMC Nephrol; 2017 Aug; 18(1):272. PubMed ID: 28841848
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease.
Cardoso MMA; Machado-Rugolo J; Lima SAM; Andrade LGM; Curado DSP; Ponce D
J Bras Nefrol; 2023; 45(1):95-101. PubMed ID: 35980102
[TBL] [Abstract][Full Text] [Related]
17. Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol.
Hansen D; Brandi L; Rasmussen K
BMC Nephrol; 2009 Sep; 10():28. PubMed ID: 19778452
[TBL] [Abstract][Full Text] [Related]
18. Importance of vitamin D receptor activation in clinical practice.
Cozzolino M; Fallabrino G; Pasho S; Olivi L; Ciceri P; Volpi E; Gallieni M; Brancaccio D
Contrib Nephrol; 2009; 163():213-218. PubMed ID: 19494616
[TBL] [Abstract][Full Text] [Related]
19. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
20. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
